2026-04-13T00:07:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1135622025-11-19T20:55:44Zcom_2072_1057col_2072_478917col_2072_478933

00925njm 22002777a 4500 dc Novohradsky, Vojtech author Zamora, Ana author Gandioso, Albert author Brabec, Viktor author Ruiz, José author Marchán Sancho, Vicente author 2017-07-10T10:15:57Z 2017-07-10T10:15:57Z 2017-04-25 2017-07-10T10:15:57Z A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminiscent cyclometalated iridium(III) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated. Iridi Càncer Somatostatina Iridium Cancer Somatostatin Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents